how big is the glp-1 market Drugs Size to Hit USD 132.79 Bn by 2035 Glucagon-like Peptide 1 (GLP-1) Market

According to Statistics Canada, 13.4% of Canadians with obesity had type 2 diabetes, compared to 2.9% of those with normal weight

These molecules act as signals that stimulate intestinal cells to release GLP-1

It helps to think in terms of patterns rather than perfection

SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis

The classification helps answer the question: "What am I actually taking, and how does it compare to what I read about online?" [Diagram suggestion: Four-quadrant matrix with axes labeled "Receptor target" (pure GLP-1 vs multi-agonist) and "Approval status" (FDA-approved vs compounded), with all medications plotted in their respective quadrants] The pattern we see in FormBlends refill data: patients often start on compounded semaglutide (Tier 4), then switch to brand-name Wegovy (Tier 1) when insurance coverage becomes available, then switch to tirzepatide (Tier 3) if weight loss plateaus

Br J Anaesth 2008